Ever Supreme Bio Technology Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING4
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +22.0 months). See all sponsors →
Open Ever Supreme Bio Technology Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Allogeneic umbilical cord mesenchymal stem cells NCT06147986 |
P2 | Recruiting | ST Elevation Myocardial Infarction | 41 | 2027-06-24 |
| CAR001 NCT06150885 |
P1/2 | Recruiting | Solid Tumor | 60 | 2027-06-30 |
| autologous dendritic cells NCT04115761 |
P2 | Recruiting | GBM | 24 | 2027-12-30 (+72 mo) |
| UMSC01 NCT05501418 |
P1/2 | Active, not recruiting | COVID-19 Infection | 75 | 2027-12-31 (+48 mo) |
| UMSC01 NCT05532943 |
P1/2 | Recruiting | Multiple Sclerosis | 41 | 2028-10-31 (+22 mo) |